{
  "id" : "grade_post_therapy_39204",
  "algorithm" : "eod_public",
  "version" : "1.0",
  "name" : "Grade Post Therapy",
  "title" : "Grade Post Therapy",
  "notes" : "**Note 1:** Leave post-therapy grade blank when\n* No neoadjuvant therapy\n* Clinical or pathological case only\n* There is only one grade available and it cannot be determined if it is clinical, pathological or post-therapy\n\n**Note 2:** Assign the highest grade from the resected primary tumor assessed after the completion of neoadjuvant therapy.\n\n**Note 3:** Codes 1-4 take priority over codes A-D.\n\n**Note 4:** The Fuhrman grade is no longer used for coding grade for Kidney cancers. The WHO/ISUP grade is now used. If the Fuhrman grade is documented, code 9.\n\n**Note 5:** Code 9 when \n* Surgical resection is done after neoadjuvant therapy and grade from the primary site is not documented\n* Grade checked “not applicable” on CAP Protocol (if available) and no other grade information is available",
  "last_modified" : "2018-03-12T16:39:59.664Z",
  "definition" : [ {
    "key" : "grade_post_therapy",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  } ],
  "rows" : [ [ "1", "G1: Nucleoli absent or inconspicuous and basophilic at 400x magnification" ], [ "2", "G2: Nucleoli conspicuous and eosinophilic at 400x magnification, visible but not prominent at 100x magnification" ], [ "3", "G3: Nucleoli conspicuous and eosinophilic at 100x magnification" ], [ "4", "G4: Marked nuclear pleomorphism and/or multinucleate giant cells and/or rhabdoid and/or sarcomatoid differentiation" ], [ "A", "Well differentiated" ], [ "B", "Moderately differentiated" ], [ "C", "Poorly differentiated" ], [ "D", "Undifferentiated, anaplastic" ], [ "9", "Grade cannot be assessed (GX); Unknown" ], [ "", "See Note 1" ] ]
}